April 22 - 26, 2024
Seattle, Washington
May 7 - 9, 2024 (Virtual)
Symposium Supporters
2024 MRS Spring Meeting
SB01.02.06

Advanced Tissue Engineering Scaffolds Incorporated with Gold Nanoparticle-Based Theranostics for Postoperative Cancer Patients

When and Where

Apr 23, 2024
3:30pm - 3:45pm
Room 428, Level 4, Summit

Presenter(s)

Co-Author(s)

Min Wang1,Lin Guo1,Qilong Zhao1,Li-wu Zheng1

The University of Hong Kong1

Abstract

Min Wang1,Lin Guo1,Qilong Zhao1,Li-wu Zheng1

The University of Hong Kong1
Cancer causes millions of human deaths each year and surgery has been the most commonly used method for treating many types of cancers. After surgical removal of the tumor, new tissues need to be formed at the resection site for restoring body functions. Scaffold-based tissue engineering has emerged as a viable approach for regenerating tissues in the body. Another major issue for many cancer patients, such as suffers of gastrointestinal (GI) tract cancer, is the high cancer recurrence rate. Therefore, new strategies should be investigated to detect and treat recurrent cancer for patients after their initial cancer treatment. In nanomedicine, nanodevices that provide both diagnostic and therapeutic functions (the so-called “theranostics”) appear to be highly promising for the early detection and effective treatment of cancers. In the current study, a new concurrent electrospinning and co-axial electrospray technology was developed for fabricating advanced tissue engineering scaffolds incorporated with gold nanoparticle (AuNP)-based theranostics for treating cancer patients. Model scaffolds designed for GI tract cancer patients were made using this technology. It was shown that a controlled release of AuNP-based theranostics could be achieved for the advanced scaffolds. The study using NIH/3T3 mouse fibroblasts indicated good biocompatibility of released theranostics. HeLa cells, which have a high-level of folate receptor (FR) expression, and MCF-7 cells, which have a low-level FR expression and thus could provide a negative control in the current study, were employed for investigating the designed functions of the theranostics. <i>In vitro</i> investigations showed that the theranostics released from scaffolds could provide both diagnostic and therapeutic functions, including strongly amplified Raman signals via the surface enhanced Raman scattering (SERS) effect, active targeting, cellular imaging and photothermal therapy for HeLa cells. Our other studies also showed the potential of these advanced scaffold for GI tract tissue regeneration. Altogether, these novel scaffolds are highly promising for offering the treatment for postoperative cancer patients.

Keywords

nanoscale

Symposium Organizers

Weibo Cai, University of Wisconsin--Madison
Bella Manshian, KU Leuven
Dalong Ni, Shanghai Jiao Tong University.
Ruirui Qiao, The University of Queensland

Symposium Support

Bronze
EXODUS BIO
JINAN NANOMEDICINE (HONG KONG) CO., LIMITED
Journal of Nanobiotechnology
KeAi-Bioactive Materials
POP Biotechnologies
Portrai Inc.
Promega Corporation
RAYSOLUTION Healthcare Co., Ltd
Shandong Madic Technology Co., Ltd.
United Well Technologies (China) Limited

Session Chairs

Ruirui Qiao
Hao Song

In this Session